KRAS mutants occurred in all subtypes (see Supplementary material, Figure S5C), supporting the emerging notion that KRAS-mutated CRC are substantially heterogeneous 5,6, the oncogenic role of KRAS varying per specific mutation and the molecular background of the tumour in which it occurs 38. The gene discussed is KRAS; the disease is neoplasm.